MicroRNA-548c-3p inhibits T98G glioma cell proliferation and migration by downregulating c-Myb

Lu,Jianyi; Zhang,Min; Yang,Xiao; Cui,Tong; Dai,Jinpo

doi:10.3892/ol.2017.5870

MicroRNA-548c-3p inhibits T98G glioma cell proliferation and migration by downregulating c-Myb

Authors:
- Jianyi Lu
- Min Zhang
- Xiao Yang
- Tong Cui
- Jinpo Dai
View Affiliations

Affiliations: Department of Medical Genetics and Developmental Biology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, P.R. China, School of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325027, P.R. China
Published online on: March 17, 2017 https://doi.org/10.3892/ol.2017.5870
Pages: 3866-3872

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs/miRs) are short non-coding RNAs (between 20 and 22 nucleotides) that regulate gene expression by binding to the 3'‑untranslated region of target mRNA, and preventing protein translation or inducing mRNA destabilization. miRNAs are predicted to target ~60% of all mRNAs, therefore providing a marked degree of regulation of a number of cellular processes. In the present study, the expression of miR‑548c‑3p was determined by reverse transcription‑quantitative polymerase chain reaction analysis and demonstrated to be markedly downregulated in clinical malignant glioma tissues and the glioma T98G cell line compared with normal human brain tissue. Transfection of miR‑548c‑3p inhibited cell proliferation by inducing G1 cell cycle arrest and also inhibited the migration of the T98G cells in vitro. Furthermore, a bioinformatic algorithm and a luciferase reporter assay identified proto‑oncogene c-Myb (c-Myb) as a potential direct target of miR‑548c‑3p. Further experiments demonstrated that the inhibition of c-Myb by miR-548c-3p partially mediated the antitumor effect of miR‑548c‑3p. The results of the present study provide the novel insight that miR-548c-3p inhibits glioma tumorigenesis by targeting c‑Myb. Therefore, miR-548c-3p may contribute to the development of improved glioma treatment.

View Figures

View References

1	Stupp R, Tonn JC, Brada M and Pentheroudakis G: High-grade malignant glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 21:(Suppl 5). v190–v193. 2010. View Article : Google Scholar : PubMed/NCBI
2	Schwartzbaum JA, Fisher JL, Aldape KD and Wrensch M: Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol. 2:494–503. 2006. View Article : Google Scholar : PubMed/NCBI
3	Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
4	Kleihues P and Ohgaki H: Primary and secondary glioblastomas: From concept to clinical diagnosis. Neuro Oncol. 1:44–51. 1999. View Article : Google Scholar : PubMed/NCBI
5	Fisher JL, Schwartzbaum JA, Wrensch M and Wiemels JL: Epidemiology of brain tumors. Neurol Clin. 25:867–890, vii. 2007. View Article : Google Scholar : PubMed/NCBI
6	McNeill KA: Epidemiology of brain tumors. Neurol Clin. 34:981–998. 2016. View Article : Google Scholar : PubMed/NCBI
7	Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
8	Lee RC, Feinbaum RL and Ambros V: The C. Elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI
9	Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR and Ruvkun G: The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 403:901–906. 2000. View Article : Google Scholar : PubMed/NCBI
10	Cheng AM, Byrom MW, Shelton J and Ford LP: Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. 33:1290–1297. 2005. View Article : Google Scholar : PubMed/NCBI
11	Tanno B, Cesi V, Vitali R, Sesti F, Giuffrida ML, Mancini C, Calabretta B and Raschellà G: Silencing of endogenous IGFBP-5 by micro RNA interference affects proliferation, apoptosis and differentiation of neuroblastoma cells. Cell Death Differ. 12:213–223. 2005. View Article : Google Scholar : PubMed/NCBI
12	Liang T, Guo L and Liu C: Genome-wide analysis of mir-548 gene family reveals evolutionary and functional implications. J Biomed Biotechnol. 2012:6795632012. View Article : Google Scholar : PubMed/NCBI
13	Rane JK, Scaravilli M, Ylipää A, Pellacani D, Mann VM, Simms MS, Nykter M, Collins AT, Visakorpi T and Maitland NJ: MicroRNA expression profile of primary prostate cancer stem cells as a source of biomarkers and therapeutic targets. Eur Urol. 67:7–10. 2015. View Article : Google Scholar : PubMed/NCBI
14	Guo J, Miao Y, Xiao B, Huan R, Jiang Z, Meng D and Wang Y: Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. J Gastroenterol Hepatol. 24:652–657. 2009. View Article : Google Scholar : PubMed/NCBI
15	Chang H, Kim N, Park JH, Nam RH, Choi YJ, Lee HS, Yoon H, Shin CM, Park YS, Kim JM and Lee DH: Different microRNA expression levels in gastric cancer depending on Helicobacter pylori infection. Gut Liver. 9:188–196. 2015. View Article : Google Scholar : PubMed/NCBI
16	Rushton JJ, Davis LM, Lei W, Mo X, Leutz A and Ness SA: Distinct changes in gene expression induced by A-Myb, B-Myb and c-Myb proteins. Oncogene. 22:308–313. 2003. View Article : Google Scholar : PubMed/NCBI
17	Rushton JJ and Ness SA: The conserved DNA binding domain mediates similar regulatory interactions for A-Myb, B-Myb and c-Myb transcription factors. Blood Cells Mol Dis. 27:459–463. 2001. View Article : Google Scholar : PubMed/NCBI
18	Ramsay RG and Gonda TJ: MYB function in normal and cancer cells. Nat Rev Cancer. 8:523–534. 2008. View Article : Google Scholar : PubMed/NCBI
19	Zhou Y and Ness SA: Myb proteins: Angels and demons in normal and transformed cells. Front Biosci (Landmark Ed). 16:1109–1131. 2011. View Article : Google Scholar : PubMed/NCBI
20	Ramkissoon LA, Horowitz PM, Craig JM, Ramkissoon SH, Rich BE, Schumacher SE, McKenna A, Lawrence MS, Bergthold G, Brastianos PK, et al: Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci USA. 110:8188–8193. 2013. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Method. 25:402–408. 2001. View Article : Google Scholar
22	Zhang B, Pan X, Cobb GP and Anderson TA: microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12. 2007. View Article : Google Scholar : PubMed/NCBI
23	Cho WC: OncomiRs: The discovery and progress of microRNAs in cancers. Mol Cancer. 6:602007. View Article : Google Scholar : PubMed/NCBI
24	Dobson JR, Taipaleenmäki H, Hu YJ, Hong D, van Wijnen AJ, Stein JL, Stein GS, Lian JB and Pratap J: hsa-mir-30c promotes the invasive phenotype of metastatic breast cancer cells by targeting NOV/CCN3. Cancer Cell Int. 14:732014. View Article : Google Scholar : PubMed/NCBI
25	Kim BH, Hong SW, Kim A, Choi SH and Yoon SO: Prognostic implications for high expression of oncogenic microRNAs in advanced gastric carcinoma. J Surg Oncol. 107:505–510. 2013. View Article : Google Scholar : PubMed/NCBI
26	Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009. View Article : Google Scholar : PubMed/NCBI
27	Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, Bignell GR, et al: The landscape of cancer genes and mutational processes in breast cancer. Nature. 486:400–404. 2012.PubMed/NCBI
28	Fedele M, Visone R, De Martino I, Troncone G, Palmieri D, Battista S, Ciarmiello A, Pallante P, Arra C, Melillo RM, et al: HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell. 9:459–471. 2006. View Article : Google Scholar : PubMed/NCBI
29	Zhou YE, O'Rourke JP, Edwards JS and Ness SA: Single molecule analysis of c-myb alternative splicing reveals novel classifiers for precursor B-ALL. PLoS One. 6:e228802011. View Article : Google Scholar : PubMed/NCBI
30	Brill LB II, Kanner WA, Fehr A, Andrén Y, Moskaluk CA, Löning T, Stenman G and Frierson HF Jr: Analysis of MYB expression and MYB-NFIB gene fusions in adenoid cystic carcinoma and other salivary neoplasms. Mod Pathol. 24:1169–1176. 2011. View Article : Google Scholar : PubMed/NCBI
31	Ganter B, Fu S and Lipsick JS: D-type cyclins repress transcriptional activation by the v-Myb but not the c-Myb DNA-binding domain. EMBO J. 17:255–268. 1998. View Article : Google Scholar : PubMed/NCBI
32	Ameh EA, Mshelbwala PM, Nasir AA, Lukong CS, Jabo BA, Anumah MA and Nmadu PT: Surgical site infection in children: Prospective analysis of the burden and risk factors in a sub-Saharan African setting. Surg Infect (Larchmt). 10:105–109. 2009. View Article : Google Scholar : PubMed/NCBI
33	Tanno B, Sesti F, Cesi V, Bossi G, Ferrari-Amorotti G, Bussolari R, Tirindelli D, Calabretta B and Raschellà G: Expression of Slug is regulated by c-Myb and is required for invasion and bone marrow homing of cancer cells of different origin. J Biol Chem. 285:29434–29445. 2010. View Article : Google Scholar : PubMed/NCBI